Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.87 |
| ▸ | TK2 | O00142 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13273343 | 1.00 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1532524 | 1.00 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13252712 | 1.00 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273573 | 1.00 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1679403 | 0.97 | TK1 (0.85) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1679401 | 0.97 | TK1 (0.85) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL11354411 | 0.96 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL5982016 | 0.93 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273340 | 0.93 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL2396529 | 0.93 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4651942-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2007-08-23 | — | — | US | claimed |
| EP-1569658-A4 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD (BB) | 2007-05-30 | — | — | EP | claimed |
| JP-2005528334-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1569658-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | Pharmassett Ltd. (BB) | 2005-09-07 | — | — | EP | claimed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | claimed |
| WO-2003053360-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD. (BB) | 2003-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | TK1 5/4885TK2 90/4885LMNA 2329/4885 |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | UMPS, ENTPD5, TK1 | TK1 3/4885TK2 54/4885LMNA 1844/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | TK1 3/4885TK2 54/4885LMNA 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.